UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2022

MEDAVAIL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-36533 (Commission File Number) 90-0772394

(I.R.S. Employer Identification Number)

4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona 85040

(Address of principal executive offices)

+1 (905) 812-0023 (Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 \Box Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 \Box Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

isuant to Section 12(0) of the Ac

Title of each class Common Stock, par value \$0.001 per share Trading Symbol MDVL

Name of each exchange on which registered The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02 Results of Operations and Financial Condition.

On November 10th, 2022, MedAvail Holdings, Inc. ("MedAvail" or the "Company") issued a press release regarding its financial and operational results for the three months ended September 30th, 2022. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information is intended to be furnished under Items 2.02 and 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On November 10th, 2022, MedAvail hosted a conference call and webcast to discuss the Company's financial and operational results for the three months ended September 30th, 2022.

Additionally, attached as Exhibit 99.2 to this Current Report on Form 8-K is an investor presentation that MedAvail may use in presentations to investors beginning November 10th, 2022.

The presentation includes a discussion of Operating Results and Adjusted EBITDA, non-GAAP (generally accepted accounting principles) financial measures. The presentation also includes reconciliations of those measures to the most directly comparable financial measures calculated and presented in accordance with GAAP.

The investor presentation attached as Exhibit 99.2 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation are "forward looking" rather than historical.

The information included in this Item 7.01 and in Exhibit 99.2 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or in the Exhibit 99.2.

Item 9.01 Financial Statement and Exhibits.

(d) Exhibits	
Exhibit No.	Description
99.1	MedAvail Holdings, Inc. Press Release dated November 10, 2022
99.2	MedAvail Holdings, Inc. Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDAVAIL HOLDINGS, INC.

Date: November 10, 2022

By:

/s/ Ramona Seabaugh

Ramona Seabaugh Chief Financial Officer



MedAvail Reports Third Quarter 2022 Financial Results

PHOENIX, Ariz. - November 10, 2022 - MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail") a technology-enabled pharmacy company, today reported financial results for the three months ended September 30, 2022.

"During the third quarter, we made significant progress on our key milestones – we achieved and exceeded our target of 100 dispensing MedCenters, delivered gross margin expansion for the second consecutive quarter, and reached savings of 26% on our cash burn rate over the fourth quarter of 2021. We are also pleased with our third quarter performance; despite some headwinds, we continued to meaningfully broaden our retail pharmacy footprint and continued to expand our technology pipeline," said Mark Doerr, chief executive officer of MedAvail. Looking ahead to the remainder of 2022 and beyond, we are confident that we are well positioned with a clear pathway to deliver long-term profitable growth, as we continue our focus and strong execution across our strategic priorities."

Recent Operational Highlights

- · Ended third quarter of 2022 with 104 MedCenter total net cumulative deployments, a 28% increase year to date
- Ended third quarter of 2022 with 103 MedCenter total net dispensing deployments, a 52% increase year to date
- Expanded partnership with Cano Health to open nine additional SpotRx locations in South Florida
- Entered into a new scalable agreement with Aegis to open one initial SpotRx in Orlando
- Announced that PharmCo Rx Pharmacy plans to implement five MedCenters in Florida under a technology agreement with MedAvail
- Ended third quarter with 11.3% gross margins, an improvement from 8.2% during the second quarter, continuing consecutive quarter over quarter margin expansion
- Achieved in the third quarter savings of 26% over the cash burn rate in the fourth quarter of 2021
- · Achieved pharmacy operating costs savings of 10%, excluding increased non-cash accelerated amortization expense, as compared to the same prior year period

Third Quarter 2022 and Recent Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended September 30, 2021.

- Total revenue increased 98% to \$11.5 millionTotal revenue by segment
 - Retail Pharmacy Services revenue increased 105% to \$11.2 million
 - Pharmacy Technology revenue remained unchanged at \$0.3 million
- Net operating loss was \$11.8 million compared to \$11.3 million
- Adjusted EBITDA loss of \$9.4 million compared to \$10.1 million
- Cash and cash equivalents as of September 30, 2022, were \$27.2 million

Full Year 2022 Financial Outlook

MedAvail expects total revenue for full year 2022 to be at least \$42 million, representing growth of at least 90% over full year 2021 revenue.

The company is raising guidance of 30 to 35 net new dispensing deployments for full year 2022 to at least 40 net new dispensing deployments.

Conference Call

MedAvail will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, November 10, 2022, to discuss its third quarter 2022 financial results. The conference call can be accessed by registering online for the live audio webcast on the "Investor Relations" section of MedAvail's website at: https://investors.medavail.com. The webcast will be archived and available for replay after the event.

Definition of Key Metrics

Net Dispensing Deployments

We define net dispensing deployments as sites that are live, meaning that such sites have payer network acceptance, pharmacy board approvals and trained clinical staff or clinical account managers.

Net Cumulative Deployments

Net cumulative deployments includes dispensing deployments and installed not yet dispensing deployments, but excludes decommissioned clinics, pilots and demo sites.

About MedAvail

MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy company, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at www.medavail.com.

Non-GAAP Financial Measures

MedAvail refers to certain financial measures that are not recognized under U.S. generally accepted accounting principles ("GAAP") in this press release, including adjusted EBITDA. See the schedules to this press release for additional information and reconciliations of such non-GAAP financial measures.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," "project," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding MedAvail's business strategy and market opportunity; potential future revenue and cost savings projections and expectations for growth and profitability; customer demand and expansion plans; margin, utilization and cost reduction improvements; improvements in deployment efficiency and speed; and customer partnerships. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of MedAvail's management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to risks

discussed under the heading "Risk Factors" in MedAvail's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 29, 2022, MedAvail's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the SEC on November 10, 2022, and other filings MedAvail makes with the SEC in the future. Additional information is also set forth in MedAvail's Annual Report on Form 10-K for the year ended December 31, 2021, MedAvail's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and other filings MedAvail makes with the SEC in the future. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and MedAvail specifically disclaims any obligation to update these forward-looking statements.

Contacts: Investor Relations Ji-Yon Yi Gilmartin Group ir@medavail.com

SOURCE MedAvail Holdings, Inc.

MEDAVAIL HOLDINGS, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)

	Three	e Months En	ded September 30,	
	2022		2021 (1)	
Revenue:				
Pharmacy and hardware revenue	\$	11,266	\$ 5,6	59
Service revenue		195	1	.33
Total revenue		11,461	5,7	92
Cost of products sold and services:				
Pharmacy and hardware cost of products sold		10,113	5,5	39
Service costs		56		67
Total cost of products sold and services		10,169	5,6	06
Operating expense:				
Pharmacy operations		4,392	3,7	50
General and administrative		6,087	5,3	20
Selling and marketing		2,126	1,9	09
Research and development		178	2	32
Total operating expense		12,783	11,2	.11
Operating loss		(11,491)	(11,02	25)
Other gain (loss), net		—		7
Interest income		—		7
Interest expense		(315)	(20	60)
Loss before income taxes		(11,806)	(11,2)	71)
Income tax expense		—		(2)
Net loss and comprehensive loss	\$	(11,806)	\$ (11,2)	73)
Net loss per share - basic and diluted	\$	(0.15)	\$ (0.3	34)
Weighted average shares outstanding - basic and diluted		80,045,995	32,750,8	331

⁽¹⁾ Certain activity was reclassified to be consistent with the current presentation, see comparative tables that follow.

MEDAVAIL HOLDINGS, INC. Operating Expense Reclassifications (in thousands) (Unaudited)

	 Three Months Ender	d September 30, 2021			
	 Current presentation	As previously reported	Change	Change	
Pharmacy operations	\$ 3,750	\$ 2,395	\$ 1	1,355	
General and administrative	5,320	6,805	(1,	1,485)	
Selling and marketing	1,909	1,779		130	
	\$ 10,979	\$ 10,979	\$	_	

MEDAVAIL HOLDINGS, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts)

	Se	ptember 30,	De	cember 31,
		2022		2021
Assets				
Current assets:				
Cash and cash equivalents	\$	27,196	\$	19,689
Restricted cash		676		400
Accounts receivable (net of allowance for doubtful accounts of \$186 thousand for September 30, 2022, \$66 thousand for December 31, 2021)		2,262		1,189
Inventories		6,401		3,916
Prepaid expenses and other current assets		2,863		2,191
Total current assets		39,398		27,385
Property, plant and equipment, net		6,370		5,692
Intangible assets, net		1,580		2,300
Right-of-use assets		2,270		2,538
Other assets		233		228
Total assets	\$	49,851	\$	38,143
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable	\$	2,006	\$	2,477
Accrued liabilities		1,383		1,530
Accrued payroll and benefits		2,869		2,733
Deferred revenue		70		83
Current portion of lease obligations		728		682
Total current liabilities		7,056		7,505
Long-term debt, net		9,751		9,538
Long-term portion of lease obligations		1,738		2,027
Total liabilities		18,545		19,070
Commitments and contingencies				
Stockholders' equity:				
Common shares (\$0.001 par value, 300,000,000 shares authorized, 80,045,696 and 32,902,048 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively)		80		33
Warrants		11,148		1,373
Additional paid-in-capital		255,642		216,685
Accumulated other comprehensive loss		(6,928)		(6,928)
Accumulated deficit		(228,636)		(192,090)
Total stockholders' equity		31,306		19,073
Total liabilities and stockholders' equity	\$	49,851	\$	38,143

MEDAVAIL HOLDINGS, INC. Supplemental Financial Information - Segments (in thousands) (Unaudited)

	Retail Pharmacy Services	Pharmacy Technology	Total		
Three Months Ended September 30, 2022					
Revenue:					
Pharmacy and hardware revenue:					
Retail pharmacy revenue	\$ 11,162	\$	\$ 11,162		
Hardware	—	—	—		
Subscription	—	104	104		
Total pharmacy and hardware revenue	11,162	104	11,266		
Service revenue:					
Software	_	94	94		
Maintenance and support	—	48	48		
Installation	—	—	—		
Professional services and other	—	53	53		
Total service revenue		195	195		
Total revenue	11,162	299	11,461		
Cost of products sold and services	10,047	122	10,169		
Segment gross profit	\$ 1,115	\$ 177	1,292		

	Retail Pharmacy Services	Pharmacy Technology	Total
Three Months Ended September 30, 2021			
Revenue:			
Pharmacy and hardware revenue:			
Retail pharmacy revenue	\$ 5,445	\$	\$ 5,445
Hardware	—	106	106
Subscription	—	108	108
Total pharmacy and hardware revenue	5,445	214	5,659
Service revenue:			
Software	_	51	51
Maintenance and support	—	44	44
Installation	_	11	11
Professional services and other	—	27	27
Total service revenue	_	133	133
Total revenue	5,445	347	5,792
Cost of products sold and services	5,366	240	5,606
Segment gross profit	\$ 79	\$ 107	186

Non-GAAP Financial Measures

To supplement our consolidated condensed financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: EBITDA, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We define Adjusted EBITDA for a particular period as net (loss) income before interest, taxes, depreciation and amortization, and as further adjusted for non-recurring revenue from stock-based compensation expense.


We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results, like onetime transaction costs related to the reverse merger. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity as well as comparisons to our competitors' operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.

MEDAVAIL HOLDINGS, INC. Unaudited Reconciliation of GAAP to Non-GAAP Measures (in thousands)

Adjustments to calculate EBITDA: Interest income Interest expense Income tax expense Depreciation and amortization ⁽¹⁾ EBITDA Adjustments as follows:	Three Months Ended September 30,						
	 2022		2021				
Net loss	\$ (11,806)	\$	(11,273)				
Adjustments to calculate EBITDA:							
Interest income	_		(7)				
Interest expense	315		260				
Income tax expense	—		2				
Depreciation and amortization ⁽¹⁾	1,616		526				
EBITDA	\$ (9,875)	\$	(10,492)				
Adjustments as follows:							
Share-based compensation expense	565		365				
Adjusted EBITDA	\$ (9,310)	\$	(10,127)				
		-					

(1) Excludes \$164 thousand and \$213 thousand in operating lease amortization for the three months ended September 30, 2022, and 2021, respectively.




Safe Harbor Statements

MedAvail Holdings, Inc. ("MedAvail") cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as "anticipate," "believe," "expand," "expect," "grow," "intend," "opportunity," "plan," "potential," "project", "target" and "will" among others. These forward-looking statements are based on MedAvail's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of the ability to project future cash utilization and resources need for contingent future liabilities and business operations, the availability of sufficient resources for combined company operations and to conduct or continue planned product development activities, the ability to execute on commercial objectives, regulatory developments and the timing and ability of MedAvail to raise additional capital to fund operations, and other factors, including, but not limited to, those factors discussed in the section entitled "Risk Factors" of our Annual Report on Form 10-K filed on March 29, 2022 and on our Quarterly Report Form 10-Q filed on November 10, 2022. Although we believe the expectations reflected in the forward-looking statements for any reason, even if new information becomes available in the future, except as may be required by law. The extent to which the impact of the COVID-19 pandemic, the ongoing military action launched by Russian forces in Ukraine, or the impact of other global economic conditions, including any economic downturn and changes to inflation or interest rates has on MedAvail's businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable and how quickly and to what extent normal economic and which they were made, except as may be required by thew

Pharmacy and Technology Businesses Powered by the MedCenter


SPOTRX	SpotRx Prosmory Get your prescriptions	TECHNOLOGY ution for pharmacy providers	Colu
 Embedding Pharmacy Services in Clinics Helps address patient adherence Quicker, more ready access to pharmacy Direct provider access to pharmacy 	Hendersen	Address labor market challenges nomically expands pharmacy hours blishes pharmacy self-checkout	Selling Me Helps Econo
Remote Dispensing – New Prescriptions	Telepharmacy & Telehealth	Automated Will Call Bin – Refills	
Increases medication adherence	(S) (S)	Improves patient access and satisfaction	\bigotimes


SpotRx: Rapid Scaling through Hub and Spoke Model




Unique embedded pharmacy model results in improved patient medication adherence and satisfaction

¹ MedAvail Third Quarter 2022 Financial Results released November 10, 2022





Medication Adherence Impact on Star Rating & Reimbursement



33% INCREASE in MedCenter Utilization Utilization of the MedCenter increased from 12.9% from August '21 to January '22 to 17.1% for the 6 months ending July '22 SpotRx 20.0% 12.9% 17.1% 18.0% Get your prescriptions filled here 17.2% MedCenter / DTC Utilization % 16.0% 14.0% 12.0% 11.1% 10.0% 8.0% Junil May22 2111-22 AU9:21 500-21 001-21 1404.21 Decili 120-22 Febril Wards Pours

First Fills Facilitated by Increasing MedCenter Utilization


Broadening Footprint with Strong Partnerships




Expanding with Strategic Partners into New Clinics and Markets



Deployment Momentum Drives Strong Revenue Growth





Historical Site Revenue Ramp


Driving Targeted Key Milestones

ceeded in Q3 2022	Continued traction
50% Growth in dispensingMedCenters to over 100 in existing markets20% Reduction in quarterly	 Planned 20% reduction in quarterly cash burn by: Gross margin expansion Greater hub pharmacy utilization as clinics onboard and mature Optimization of clinic and pharmacy labor
cash burn 8-9% Gross margin target by	 G&A leverage: existing team able to support increase in scale Targeting mid-teens¹ long-term gross margin
Q1 2023	 Technology business segment building a pipeline for 2023², leveraging EPIC integration

¹ Target based on industry average (Drug Channels Institute, Adam Fine, 2021)
 ² Based on Second Quarter Earnings Call commentary on August 11, 2022



Complementary Deployment Models Drive Expansion



Investment Highlights




Proprietary technology platform enables on-site pharmacy integral to medication adherence

Highly scalable hub & spoke model enables margin expansion & operating leverage

Large \$16B TAM in current states of operation with ~\$500M from ~700 clinics existing SpotRx partners

Near-term technology market expansion opportunities with pharmacy management integrations



Consolidated Statement of Operations (Unaudited)

(In thousands)	Q	1 2021	Q	2 2021	Q	3 2021	G	4 2021	G	1 2022	Q	2 2022	Q3 2022
Revenue:			-										
Pharmacy and hardware revenue	\$	3,781	\$	4,725	\$	5,659	\$	6,954	\$	9,014	\$	10,930	\$ 11,266
Service revenue		246		305		133		326		100		254	195
Total revenue	1.0	4,027	5U	5,030		5,792	-	7,280	12	9,114	1	11,184	11,461
Cost of products sold and services:													
Pharmacy and hardware cost of sales		3,526		4,679		5,539		7,562		8,563		10,151	10,113
Service cost of sales		181		178		67		80		50		115	56
Total cost of products sold and services		3,707		4,857		5,606		7,642	_	8,613		10,266	10,169
Operating Expense: (1)									-				
Pharmacy operations		2,593		3,085		3,750		4,068		3,929		3,648	4,392
General and administrative		5,676		5,737		5,320		5,544		6,535		6,100	6,087
Selling and marketing		1,534		1,613		1,909		2,148		2,313		2,307	2,126
Research and development		168		201		232		248		493		281	178
Merger expenses		-		-		-		-		-		-	-
Total operating expense		9,971		10,636		11,211		12,008		13,270		12,336	12,783
Operating loss		(9,651)	(10,463)		(11,025)		(12,370)		(12,769)		(11,418)	(11,491
Other gain (loss), net		161		38		7		-		-		-	-
Interest income		40		27		7		5		1		-	2
Interest expense		(2)		(66)		(260)		(261)		(254)		(276)	(315
Loss before income taxes		(9,452)	(10,464)	1	(11,271)		(12,626)		(13,022)		(11,694)	(11,806
Income tax expense		-		-		(2)		-		-		(24)	-
Netloss	\$	(9,452)	\$ (10,464)	\$	(11,273)	\$	(12,626)	\$	(13,022)	\$	(11,718)	\$ (11,806

(1) Certain operating expense activity was reclassified to be consistent with the presentation in Q4 2021. See comparative table that follows.

Operating Expense Reclassifications (Unaudited)

		Q1			
(In thousands)	Current	Presentation	As Previo	usly Reported	Change
Pharmacy operations	s	2,593	\$	1,911	\$ 682
General and administrative		5,676		6,515	(839)
Selling and marketing		1,534		1,377	157
Research and development		168		168	(-)
	s	9,971	\$	9,971	\$ -
		Q2			
(In thousands)	Current	Presentation	As Previo	usly Reported	Change
Pharmacy operations	s	3,085	\$	2,292	\$ 793
General and administrative		5,737		6,646	(909)
Selling and marketing		1,613		1,497	116
Research and development		201		201	-
	s	10,636	\$	10,636	\$ -
		Q3			
(In thousands)	Current	Presentation	As Previo	usly Reported	Change
Pharmacy operations	s	3,750	\$	2,395	\$ 1,355
General and administrative		5,320		6,805	(1,485)
Selling and marketing		1,909		1,779	130
Research and development		232		232	

\$ 11,211 \$ 11,211 \$

Revenue and Cost of Products Sold and Services (Unaudited)

				Q1 2021			Q2 2021								23 2021		Q4 2021							
(In thousands)		Retail Pharmacy Services		Pharmacy Technology		Total	Retail Pharmacy Services		Pharmacy Technology		Total		Retail Pharmacy Services		Pharmacy Technology			Total	Retail Pharmacy Services		Pharmacy Technology		Total	
Revenue:				roomorgy		Total			100	interegy	_	Total	-		10.	onnorogy		Total	-			Johnology		otar
Pharmacy and hardware revenue:																								
Retail pharmacy revenue	S	3,418	;	\$ -	\$	3,418	\$	4,494	\$	-	\$	4,494	\$	5,445	\$	-	\$	5,445	\$	6,846	\$	-	\$	6,846
Hardware (1)		-		241		241		14		123		123		-		106		106		-		-		-
Subscription		-		122		122		-		108		108		-		108		108		-		108		108
Total pharmacy and hardware revenue	-	3,418	1	363		3,781		4,494		231		4,725		5,445		214		5,659	-	6,846		108		6,954
Service revenue:	-							10																-
Software integration (1)		2		-				1		-		-		-		-		-		-		-		1
Software		-		33		33		-		41		41		-		51		51		-		134		134
Maintenance and support				31		31		-		40		40		-		44		44				47		47
Installation		-		16		16		-		12		12		-		11		11		2		-		-
Professional services and other				166		166		-		212		212				27		27		-		145		145
Total service revenue	-	-		246		246	198 	-		305		305		-		133		133		-		326		326
Total revenue		3,418		609		4,027	- 165 	4,494		536		5,030		5,445		347		5,792		6,846		434		7,280
Cost of products sold and services		3,329	1	378		3,707	200	4,435		422		4,857		5,366		240		5,606		6,901		741		7,642
Segment gross profit (loss)	S	89		\$ 231	\$	320	\$	59	\$	114	\$	173	\$	79	\$	107	\$	186	\$	(55)	\$	(307)	\$	(362)

Revenue and Cost of Products Sold and Services (Unaudited)

	Q1 2022					Q2 2022					Q3 2022							
(In thousands)	Pha	Retail armacy rvices		rmacy		Total	Ph	Retail armacy ervices		armacy hnology		Total	Ph	Retail armacy ervices		rmacy		Total
Revenue:													-					
Pharmacy and hardware Revenue:																		
Retail pharmacy revenue	s	8,849	S	-	s	8,849	S	10,641	S	-	s	10,641	S	11,162	S	-	S	11,162
Hardware		-		56		56		-		180		180		-		-		-
Subscription		-		109		109		2		109		109				104		104
Total pharmacy and hardware revenue	_	8,849		165		9,014		10,641		289		10,930	-	11,162		104		11,266
Service revenue:	2						S											
Software integration		100		1.21		12				121		12		120		-		-
Software		-		48		48		-		86		86		-		94		94
Maintenance and support		-		32		32		-		47		47		-		48		48
Installation		-		6		6		-		71		71		-		2		
Professional services and other		-		14		14				50		50		-		53		53
Total service revenue		-		100		100		-		254		254		-		195		195
Total revenue		8,849		265		9,114	_	10,641		543		11.184		11,162		299		11,461
Cost of products sold and services		8,482		131		8,613		9,930		336		10,266		10,047		122		10,169
Segment gross profit (loss)	S	367	S	134	S	501	S	711	S	207	S	918	S	1,115	S	177	S	1,292

Adjusted EBITDA – Non-GAAP Reconciliation (Unaudited)

(In thousands)	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022
Net loss	\$ (9,452)	\$(10,464)	\$(11,273)	\$ (12,626)	\$(13,022)	\$(11,718)	\$(11,806)
Adjustments to calculate EBITDA:							
Interest expense, net	(38)	39	253	256	253	276	315
Income tax expense	-	-	2	-	-	24	-
Depreciation and amortization	340	392	526	569	432	485	1,616
EBITDA	(9,150)	(10,033)	(10,492)	(11,801)	(12,337)	(10,933)	(9,875)
Adjustments as follows:							
Share-based compensation expense	260	323	365	257	564	612	565
Inventory adjustment	-		-	626	-		-
Adjusted EBITDA	\$ (8,890)	\$ (9,710)	\$(10,127)	\$ (10,918)	\$(11,773)	\$(10,321)	\$ (9,310)

Non-GAAP Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: EBITDA, and Adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We define Adjusted EBITDA for a particular period as net (loss) income before interest, taxes, depreciation and amortization, share-based compensation expense, and non-recurring inventory impairment charges.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results, like one-time transaction costs related to the reverse merger. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity as well as comparisons to our competitors' operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.